McCoach and collaborators performed a survey of a laboratory cohort of ALK-positive lung cancer patients whit ctDNA tested by G360 assay to determine the clinical utility of plasma-based comprehensive genomic profiling. The gene discussed is ALK; the disease is lung cancer.